Congress Approved Billions for Science. The Money Is Sitting Unspent. Here Is Why — and What Grant Seekers Should Do About It.

Something unusual is happening in federal science funding, and it should alarm every researcher, university, and nonprofit that depends on federal grants. Congress passed FY2026 spending bills that largely rejected the administration's proposed cuts to science agencies. NIH received $48.7 billion — a $415 million increase. NSF got $8.75 billion. NASA kept $24.4 billion. DOE's Office of Science held at $8.4 billion. On paper, federal science funding is stable, even growing.

But the money is not moving.

As Granted News reported, a growing gap has opened between what Congress appropriates and what agencies actually disburse to grantees. NIH is months behind on dispersing the bulk of its FY2026 funding. NASA has seen over $100 million in FY2025 funds frozen by the Office of Management and Budget. Across the federal research enterprise, appropriated dollars are sitting in agency accounts while the laboratories, universities, and small businesses that were supposed to receive them scramble for alternatives.

This is not a budget shortfall. It is a disbursement crisis — and understanding the mechanisms behind it is essential for anyone whose work depends on federal funding.

The Mechanics of Impoundment

The word "impoundment" carries constitutional weight. Under the Impoundment Control Act of 1974, the president cannot simply refuse to spend money that Congress has appropriated. The law was passed in direct response to President Nixon's attempts to unilaterally withhold funds from programs he opposed. It requires the president to notify Congress through either a "deferral" (temporary delay) or a "rescission" (permanent cancellation), and Congress must approve any rescission within 45 days or the funds must be released.

The current administration has taken a different approach. The White House has argued that appropriations levels represent a ceiling, not a spending floor — that Congress can appropriate funding and the administration can choose not to spend some or all of it. This interpretation, if sustained, would fundamentally alter the relationship between the legislative and executive branches on spending authority.

The Center on Budget and Policy Priorities has characterized this as the administration announcing it will "for the first time ever, misuse the Impoundment Control Act to illegally withhold funding until it expires, whether Congress acts or not." The practical effect is the same as a budget cut, but without requiring congressional approval.

For grant seekers, the distinction between "not appropriated" and "appropriated but not disbursed" matters enormously. A researcher who sees that NIH received $48.7 billion and plans their lab's operations accordingly discovers, months into the fiscal year, that their renewal grant has not been funded — not because the money does not exist, but because the money has not been released.

The OMB Spending Plan Requirement

The primary mechanism slowing disbursements is a new Office of Management and Budget memo requiring federal agencies to submit detailed spending plans before they can release appropriated funds. Previously, once Congress passed an appropriations bill and the president signed it, agencies could begin making awards against their authorized levels with relative speed. The new OMB process adds an additional review layer.

The requirement is not unreasonable in principle — greater transparency in federal spending serves legitimate oversight goals. In practice, it has created a bottleneck. NIH, which manages tens of thousands of active grants, must now justify its spending allocations in granular detail before OMB will authorize disbursement. The result is months of delay during which researchers who expected continuous funding face gaps.

Bloomberg Government reported that research advocates worry the delays are not merely administrative. If funds remain unspent long enough, the administration could attempt to claw them back or restructure them into multiyear grants with conditions that limit researcher independence. The fear is that delay is not the endgame — it is the mechanism for achieving funding changes that Congress explicitly rejected.

What $100 Billion in Delayed Science Funding Looks Like on the Ground

The aggregate numbers obscure the human reality. When a grant renewal is delayed by three or six months, the impact cascades through an entire research operation.

A principal investigator at a university medical center who expected their R01 renewal in October 2025 may still be waiting in March 2026. Their postdoctoral researchers, funded by that grant, face salary gaps. Their graduate students cannot purchase reagents or schedule experiments. Equipment maintenance contracts lapse. Collaborators at other institutions, who were counting on subcontract funding, delay their own work.

Universities typically bridge short funding gaps with institutional reserves. But when delays affect dozens or hundreds of grants simultaneously — as they do when an agency's entire disbursement pipeline slows — institutional reserves are exhausted quickly. Smaller universities and minority-serving institutions, which have thinner financial cushions, are hit hardest.

The downstream effects extend beyond individual labs. Clinical trials that depend on federal funding face enrollment delays. Environmental monitoring programs miss data collection windows that cannot be repeated. Infrastructure projects miss construction seasons. Research timelines measured in years are disrupted by funding delays measured in months.

NASA provides a specific illustration. Senator Adam Schiff and colleagues publicly demanded an end to what they called "illegal cuts," noting that OMB directed agencies to freeze over $100 million in appropriated FY2025 science funds at NASA alone. These are not proposed budget reductions that Congress could debate. They are post-appropriation holds on money that Congress has already authorized and the president has signed into law.

Congress Saw This Coming

The FY2026 appropriations bills include language specifically designed to prevent the kind of spending impoundment that is now occurring. Agencies and departments are "generally not permitted to reallocate or reprogram funds" appropriated by the 2026 bills. Congress explicitly blocked several administration priorities — rejecting the proposed 15 percent cap on NIH indirect cost reimbursement rates, maintaining Pell Grant maximums despite proposed cuts, and preserving programs like TRIO and GEAR UP that the administration sought to eliminate.

The FY2026 Commerce, Justice, and Science bill includes reporting requirements designed to create accountability — forcing agencies to document their spending patterns and justify any deviations from congressional intent.

But anti-impoundment provisions are only as strong as their enforcement. The Impoundment Control Act has always relied on a combination of congressional pressure, GAO oversight, and ultimately court action to compel compliance. When an administration is willing to test those boundaries, the enforcement mechanism is slow. Researchers cannot wait for a court ruling expected in 18 months when their lab needs funding now.

The paradox is sharp: Congress protected science funding from cuts more effectively than many observers expected, as Granted News covered. NSF, NASA, NOAA, and EPA all preserved significant budget levels against proposed reductions of 30 to 47 percent. But the legislative victory means less if the executive branch can achieve the same result through administrative delay.

Historical Context: This Has Happened Before

Federal science funding has weathered political storms before, but the current situation has features that distinguish it from prior episodes.

The 2013 sequestration forced across-the-board cuts of approximately 5 percent to research agencies. The cuts were painful but predictable — every agency knew its reduced budget and could plan accordingly. Researchers could calculate their odds and adjust.

The 2018-2019 government shutdown suspended agency operations entirely for 35 days. NIH stopped reviewing grant applications. NSF froze new awards. But when the shutdown ended, agencies resumed normal operations quickly because the appropriations framework remained intact.

The current situation is different because the appropriations framework is intact — Congress did its job and funded science — but the executive branch is interposing itself between appropriation and disbursement in ways that the system was not designed to handle. The money exists. The authorizations exist. The mechanism preventing funds from reaching researchers is administrative, not legislative.

This distinction matters for strategy. During sequestration, the response was to advocate for restored funding. During shutdowns, the response was to wait. During an impoundment crisis, the response must be different: it requires both advocacy for disbursement of existing funds and practical adaptation to an uncertain timeline.

What Grant Seekers Should Do Now

The worst response to the funding paradox is paralysis. The second worst is pretending it is not happening. Here is what researchers and institutions should actually do.

Track disbursement, not appropriation. When evaluating your funding pipeline, do not assume that an appropriated budget line means money is available. Monitor NIH Reporter, NSF Award Search, and agency notices for actual award announcements. The gap between what agencies are authorized to spend and what they are actually spending is the metric that matters right now.

Activate bridge funding conversations early. If you have a pending renewal or competing continuation, talk to your institution's sponsored research office now about bridge funding options. Do not wait until the award should have arrived but did not. Universities, medical centers, and research institutions are developing emergency bridge mechanisms, but demand will exceed supply.

Diversify across agencies and sectors. The disbursement bottleneck is not uniform across all agencies. Some agencies are moving faster than others. DOE's Office of Science, for example, has a different operational cadence than NIH. Defense research funding operates through different channels. Foundations are deploying emergency funds specifically to bridge gaps left by federal delays — organizations like Kresge, the Robert Wood Johnson Foundation, and others are offering rapid-response grants to researchers affected by funding disruptions.

Pursue state-level funding. Multiple states are creating their own research funds to backfill federal cuts and delays. California, New York, Illinois, and Massachusetts have all announced or expanded state research funding programs. These programs often have shorter application timelines and faster disbursement than federal agencies.

Engage with your congressional delegation. Congress appropriated this money. Individual members of Congress have both the authority and the political motivation to pressure agencies to disburse it. Specific, documented cases of delayed funding — "My NIH R01 renewal was due in October and has not been issued" — carry more weight than general complaints about the funding climate. Congressional staff who handle appropriations and oversight can intervene with agencies directly.

Apply for everything you are qualified for. In an environment where some awards will be delayed or redirected, casting a wider net is prudent. The SBIR/STTR programs were just reauthorized through 2031, and agencies are expected to begin issuing new solicitations in March and April. NSF's Tech Labs initiative will release significant funding later in FY2026. DOE's early career research programs remain active. Do not let frustration with the current environment reduce your application volume.

The Longer Game

The science funding paradox will resolve — either through court action compelling disbursement, through congressional pressure forcing agency compliance, through a change in OMB policy, or through a change in administration. The Impoundment Control Act has survived previous challenges because the principle it embodies — that Congress controls the purse — is foundational to constitutional governance.

But resolution may take years. Researchers whose careers depend on continuous funding do not have years to wait. The institutions that will navigate this period most successfully are those that treat the paradox as a structural feature of the current environment rather than a temporary disruption — building diversified funding portfolios, maintaining institutional bridge reserves, and keeping meticulous records of delayed disbursements for the legal and political battles ahead.

The money Congress appropriated for American science is real. The authorization is real. The gap between authorization and disbursement is the problem — and closing that gap requires pressure from every direction: legal, political, and institutional. Grant seekers who understand the mechanics of the paradox can advocate more effectively for their own funding while adapting their strategies for an uncertain timeline.

Platforms like Granted help researchers and institutions track funding opportunities across federal, state, and foundation sources in real time — ensuring that when one funding stream slows, alternatives are visible and actionable before the gap becomes a crisis.